LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 108 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $50,781 | -28.5% | 44,939 | 0.0% | 0.00% | -33.3% |
| Q2 2022 | $71,004 | +2.6% | 44,939 | 0.0% | 0.00% | +50.0% |
| Q1 2022 | $69,206 | -47.0% | 44,939 | -15.7% | 0.00% | -50.0% |
| Q4 2021 | $130,546 | -2.8% | 53,284 | -0.0% | 0.00% | -20.0% |
| Q3 2021 | $134,326 | -11.6% | 53,304 | 0.0% | 0.01% | -16.7% |
| Q2 2021 | $151,916 | +21.3% | 53,304 | 0.0% | 0.01% | +20.0% |
| Q1 2021 | $125,264 | +508.1% | 53,304 | +355.4% | 0.01% | +400.0% |
| Q4 2020 | $20,599 | +62.7% | 11,704 | -13.4% | 0.00% | 0.0% |
| Q3 2020 | $12,661 | +105408.3% | 13,518 | +96457.1% | 0.00% | – |
| Q2 2020 | $12 | 0.0% | 14 | 0.0% | 0.00% | – |
| Q1 2020 | $12 | 0.0% | 14 | 0.0% | 0.00% | – |
| Q4 2019 | $12 | -14.3% | 14 | 0.0% | 0.00% | – |
| Q3 2019 | $14 | – | 14 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,935,485 | $55,198,000 | 4.16% |
| Raffles Associates | 1,930,536 | $3,050,000 | 3.32% |
| Defender Capital, LLC. | 5,131,935 | $8,108,000 | 3.18% |
| Prescott General Partners LLC | 1,851,851 | $2,926,000 | 0.20% |
| DAFNA Capital Management LLC | 140,000 | $221,000 | 0.06% |
| Laurion Capital Management LP | 2,422,367 | $3,827,000 | 0.06% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $71,000 | 0.05% |
| Fort Sheridan Advisors LLC | 78,931 | $125,000 | 0.04% |
| Long Focus Capital Management, LLC | 215,000 | $340,000 | 0.04% |
| MORGAN JESS S & CO INC | 20,000 | $32,000 | 0.03% |